Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.

导出 OA

翻译打印收藏纠错

第一作者： Peter J,Klauck

第一单位： Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.

作者： Peter J,Klauck ^[1] ; Stacey M,Bagby ^[1] ; Anna,Capasso ^[2] ; Erica L,Bradshaw-Pierce ^[1] ; Heather M,Selby ^[3] ; Anna,Spreafico ^[2] ; John J,Tentler ^[4] ; Aik Choon,Tan ^[1] ; Jihye,Kim ^[1] ; John J,Arcaroli ^[1] ; Alicia,Purkey ^[2] ; Wells A,Messersmith ^[1] ; Keisuke,Kuida ^[2] ; S Gail,Eckhardt ^[1] ; Todd M,Pitts ^[1]

作者单位： Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. ^[1] University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. ^[2] Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. ^[3] Takeda California, San Diego, CA, USA. ^[4] Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA. ^[5] Division of Medical Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. todd.pitts@ucdenver.edu. ^[6] University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA. todd.pitts@ucdenver.edu. ^[7]

关键词 Colorectal cancer Patient-derived xenograft Plk1 TAK-960